Latest News and Press Releases
Want to stay updated on the latest news?
-
Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
-
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
-
September 10 – 12, 2019 Workshops, September 10, 2019 Aloft Boston Seaport District 401-403 D. St., Boston, MA 02210 Executive Chairman/CSO/Interim CEO...
-
Glen Rock, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
-
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
-
Glen Rock, N.J, Jan. 03, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of...
-
December 11 – 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston, MA SVP R&D leading workshop on Financial Planning and Commercial DevelopmentSVP R&D to present...
-
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
-
Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
-
Glen Rock, N.J, June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of...